Cardiovascular Effects of Diabetes Drugs: Making the Dark Ages Brighter With CAROLINA

Potential Conflicts of Interest: All authors are involved in the CAROLINA Steering Committee. Dr. Rosenstock has also served on scientific advisory boards and received honorarium or consulting fees from Pfizer, Roche, Sanofi, Novo Nordisk, Eli Lilly, MannKind, GlaxoSmithKline, Takeda, Daiichi Sankyo, Johnson & Johnson, Novartis, Boehringer Ingelheim, and Lexicon. He has also received grants/research support from Merck, Pfizer, Sanofi, Novo Nordisk, Roche, Bristol-Myers Squibb, Eli Lilly, Forest, GlaxoSmithKline, Takeda, Novartis, AstraZeneca, Amylin, Johnson & Johnson, Daiichi Sankyo, MannKind, Lexicon, and Boehringer Ingelheim. Dr. Marx served as a speaker for AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Cordis, GlaxoSmithKline, Lilly, Merck Sharpe & Dohme, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, and Takeda and as a consultant for AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Genfit, GlaxoSmithKline, Merck Sharpe & Dohme, Novo Nordisk, Roche, Sanofi, and Takeda. He received unrestricted research grants from Boehringer Ingelheim, GlaxoSmithKline, Merck Sharpe & Dohme, and Takeda and also participated in clinical trials sponsored by Boehringer Ingelheim and Roche. Drs. Johansen and Wörle are employed by Boehringer Ingelheim.